Warby Parker Inc. WRBY R2KR3KPHARMA
Company Overview
Warby Parker Inc. sells eyewear products through its retail and e-commerce platform in the United States and Canada. The company offers eyeglasses and sunglasses; and single-vision, progressive, light-responsive, polarized, blue-light-filtering, tinted, non-prescription, and contact lenses. It also provides accessories, such as cases, pouches, lenses kit with anti-fog spray, travel cases, lenses cloth, anti-fog lens spray, and sun clip-ons through its stores, website, and mobile apps. In addition, the company offers eye exams and vision tests, as well as optical services. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York.
Why Investors Should Care
Revenue has grown at a 18.7% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $871.90M (+13.0% YoY); net profit $1.64M.
- Trailing 12 Months Year-on-year growth — revenue +9.8%, earnings -9.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 18.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 18.67% |
| 1 Year: | 9.80% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -9.60% |
Stock Price Performance
| 1 Year: | -3.36% |
| 6 Months: | +13.59% |
| 3 Months: | +4.22% |
| 1 Month: | -1.37% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)52.63 · Neutral
P/E of 431.83 is above the sector median of 25.45 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 18.7% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 431.8.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | WRBY Warby Parker Inc. R2KR3KPHARMA | 25.91 | 431.83 | $2.80B | 0.00% | -0.93% | 2.06% | 18.67% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 104.09M | 138.97M | 131.56M | 137.37M | 153.22M | 149.62M | 148.78M | 171.97M | 166.09M | 169.85M | 200.00M | 188.22M | 192.45M | - | 223.78M | 214.47M | 221.68M | 211.97M | 242.45M | 235.51M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 97.80M | 100.87M | 101.73M | 100.92M | 111.41M | - |
| Gross Profit | - | - | 63.98M | 83.78M | 78.05M | 79.66M | 89.65M | 86.35M | 84.42M | 94.79M | 90.64M | 92.73M | 113.46M | 105.38M | 104.87M | - | 125.98M | 113.61M | 119.94M | 111.04M | 131.04M | 136.46M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 123.51M | 118.13M | 116.38M | 117.89M | 129.37M | - |
| Operating Income | - | - | -41.34M | 3.02M | -8.81M | -91.98M | -33.74M | -32.08M | -23.67M | -12.43M | -18.23M | -19.77M | -5.13M | -8.96M | -6.61M | - | 2.47M | -4.53M | 3.57M | -6.85M | 1.67M | 3.17M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.63M | 7.96M | 16.10M | 6.25M | 15.44M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.93M | -2.54M | 5.75M | -5.09M | 4.00M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.45M | -789.00K | -125.00K | 862.00K | 821.00K | - |
| Net Income | 2.78M | -12.79M | -41.61M | 3.01M | -10.31M | -91.07M | -34.13M | -32.17M | -10.81M | -10.81M | -15.93M | -17.41M | -2.68M | -6.76M | -4.07M | - | 3.47M | -1.75M | 5.87M | -5.95M | 3.18M | 4.64M |
| Diluted EPS | - | - | -0.78 | -0.03 | -0.35 | -1.45 | -0.30 | -0.28 | -0.21 | -0.09 | -0.14 | -0.15 | -0.02 | -0.06 | -0.03 | - | 0.03 | -0.01 | 0.05 | -0.05 | 0.03 | 0.04 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 370.46M | 393.72M | - | 598.11M | 669.76M | 771.32M | 871.90M |
| Cost of Revenue | - | - | - | 257.05M | 304.54M | 344.48M | 401.33M |
| Gross Profit | 223.11M | 231.94M | - | 341.06M | 365.22M | 426.83M | 470.58M |
| Operating Expenses | - | - | - | 452.26M | 437.22M | 456.95M | 475.92M |
| Operating Income | -1.66M | -55.63M | - | -111.20M | -72.00M | -30.11M | -5.34M |
| EBITDA | - | - | - | -79.34M | -33.44M | 15.75M | 44.94M |
| Interest Expense | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | -109.90M | -62.76M | -19.52M | 3.04M |
| Tax Provision | - | - | - | 497.00K | 433.00K | 875.00K | 1.40M |
| Net Income | 0 | -55.92M | - | -110.39M | -63.20M | -20.39M | 1.64M |
| Diluted EPS | -1.10 | -1.05 | - | -0.96 | -0.54 | -0.17 | 0.01 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 444.75M | - | 568.71M | 580.31M | 676.49M | 720.92M |
| Current Assets | - | - | - | - | 294.57M | 298.62M | 326.05M | 352.44M |
| Cash & Equivalents | - | - | 314.08M | - | 208.59M | 216.89M | 254.16M | 286.36M |
| Inventory | - | - | - | - | 68.85M | 62.23M | 52.34M | 44.51M |
| Receivables | - | - | - | - | 1.44M | 1.78M | 1.95M | 3.29M |
| Total Liabilities | - | - | 136.34M | - | 282.06M | 278.52M | 336.42M | 353.19M |
| Current Liabilities | - | - | 105.33M | - | 129.56M | 127.09M | 130.35M | 150.13M |
| Long Term Debt | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | 173.38M | 174.46M | 225.35M | 233.15M |
| Total Equity | -133.59M | -189.45M | -198.10M | - | 286.65M | 301.79M | 340.07M | 367.73M |
| Shares Outstanding | - | - | - | - | 115.34M | 118.16M | 120.85M | 122.45M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 21.39M | 32.76M | - | 10.37M | 60.99M | 98.74M | 110.78M |
| Investing Cash Flow | -32.63M | -20.07M | - | -60.18M | -54.67M | -66.03M | -67.05M |
| Financing Cash Flow | -83.36M | 245.94M | - | 3.29M | 2.87M | 4.96M | -12.00M |
| Capital Expenditure | -32.63M | -20.07M | - | -60.18M | -53.67M | -64.03M | -67.05M |
| Free Cash Flow | -11.24M | 12.69M | - | -49.81M | 7.32M | 34.71M | 43.74M |
| Net Change in Cash | - | - | - | -46.52M | 9.19M | 37.67M | 31.74M |
| Share Buybacks | 79.47M | 0 | 8.09M | 0 | 0 | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | 60.2% | 58.9% | - | 57.0% | 54.5% | 55.3% | 54.0% |
| Operating Margin % | -0.4% | -14.1% | - | -18.6% | -10.7% | -3.9% | -0.6% |
| Net Margin % | 0.0% | -14.2% | - | -18.5% | -9.4% | -2.6% | 0.2% |
| ROE % | -0.0% | 28.2% | - | -38.5% | -20.9% | -6.0% | 0.4% |
| ROCE % | - | -16.4% | - | -25.3% | -15.9% | -5.5% | -0.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.39% | 15.58M | $394.11M |
| 2 | Blackrock Inc. | 14.14% | 15.31M | $387.33M |
| 3 | JPMORGAN CHASE & CO | 10.27% | 11.11M | $281.11M |
| 4 | Durable Capital Partners Lp | 5.91% | 6.40M | $161.83M |
| 5 | Vanguard Portfolio Management LLC | 5.53% | 5.98M | $151.38M |
| 6 | Vanguard Capital Management LLC | 4.15% | 4.49M | $113.53M |
| 7 | State Street Corporation | 3.87% | 4.18M | $105.88M |
| 8 | Vaughan Nelson Investment Management, L.P. | 2.87% | 3.11M | $78.61M |
| 9 | Geode Capital Management, LLC | 2.38% | 2.57M | $65.05M |
| 10 | Fuller & Thaler Asset Management Inc. | 2.21% | 2.40M | $60.65M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for WRBY
Why Is Warby Parker (WRBY) Stock Soaring Today - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPWUVUNHEtVFRTa2JaUl83LXJnT2xYVnVPTmgyTkhuVlRMdG9nRTNVYjFYUDEyYkYzQlhXcnF3OW9mYWg3RVhaNUQzQzVoMlNNTy1pd2tQUnlHdENNREd0NFhvOHpIVkZXUlVOWWhZMmJvNW5qYy11RTNOVndPSEdPWHY4MGoxMVU3aUlTSj…
Warby Parker Inc (WRBY) Stock Up 12.5% but GF Value Says Overval - GuruFocus
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNZWowNFFNZ2UxbnVTanhJODR2U2pqRlRHbmY5dVNvcXktUjMwdm1PRXhfY0xMaXdCdVlpZkdBVE9YSUljeUxXX05LeWxGVUNUcm1GSzlrTVNGb3NfWVBMaEtMYm4wNndZZmpCWGhfXy1kVzdBbHNmOTR0RURicjFod2JOdDJDZEZGZ0FBaT…
WRBY Stock Slips: Wall Street, Retail Traders Not Impressed Enough With Google, Samsung Smart Glass Tie-Up - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxPbXdraHY2c2wxOFFIYzZ3cG5FcFpzRDJfem85OWx5QmJRUUdnSkJNNmYwcGlvLWJYMTlvcDUtVDhyX0ZrNDBSY2REQkFhSDJqM3VhQU5rSzJGRVZoazRSbERhbnFjYmdLYm9NQWdGUFJSMHA5cXNUREZndjNhNWhXQXUxdkZoZThUcFV3MW…
Warby Parker (WRBY) Surges 12.5%: Is This an Indication of Further Gains? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxQSm41ekZrWHR4LWpIVzdUeUZxelhfd1F6b3R1ZDNZMVlLTGtkRHBuMGxYZVhjeTdHNFlVaktTUWl4OWRjODI2T3cyMF9VUWl0T0dxdENhSm1hVnhHdmNRRjRuaGU0UWxBUHVsOWlEdUhUUkFabVRHUjJWeUV4MVdIZkdjRW16TWhYUkRaOD…
Warby Parker Stock Jumped Nearly 13% in a Day. Here’s Where the Stock Could Go by 2030 - TIKR.com
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPZm9CM2pUNTN4ejdNMDAwa1JVN1lNdGxTOU10UnVkSWJJWXVSZW5VUVljOU5rLXpxODFMeXYtZ1RWbWE4ajd1ZzBsTENfNlhGSzJXb2lGNWtvVVdmVUhuVE1vdTZlS2c2RFVSSnRkalBWalFTRHlYUjlYaVpBcEhTb0pBNjdtNnZGbFd0VH…
Warby Parker: Not Worth Its Premium As Growth Slows (NYSE:WRBY) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxQWkNFYlR5MjZnNVl1M0pRQ0ZZaHN2MHFwdVNORDhJQ3pFb05lNm5IMG9iOTJzOHhwNVdpcjdLRUdNejZQWFhwQXh3RXlsWEUzQ1dmbTREQUJLNzlfUnBEcTNlS2ZJMHdIVktVQVRKcldWMHBfWnZ1X0pPSTVWZk55bmpwdnluYlNwNVF2S0…
WRBY — Frequently Asked Questions
What is the current share price of Warby Parker Inc. (WRBY)?
As of 2026-10-23 16:27 PDT, Warby Parker Inc. (WRBY) trades at $25.91 on NYSE. Its 52-week range is $16.49 to $30.34.
What is the market capitalisation of WRBY?
Warby Parker Inc. (WRBY) has a market capitalisation of $2.80B on NYSE.
What is the P/E ratio of WRBY?
WRBY trades at a trailing price-to-earnings (P/E) ratio of 431.83. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 7.35.
What is the return on equity (ROE) of WRBY?
WRBY has a return on equity (ROE) of 2.06%. Its return on capital employed (ROCE) is -0.93%.
Is WRBY a good stock to buy?
This page provides a data-driven analysis of Warby Parker Inc. (WRBY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.